SOLID TUMORS

This early-stage trial tests an experimental drug called IMP321, which aims to boost the immune system's ability to fight cancer. It is given alongside standard treatments like chemotherapy or immunotherapy to people with advanced solid tumors that have spread. The main goals are…

This early-stage trial tests a new treatment for children and young adults with high-risk solid tumors that have not responded to standard therapy. The approach uses a patient's own immune cells, trained to recognize multiple cancer targets, to attack the tumor. The main goal is …

This study tests the safety and effectiveness of the drug pembrolizumab in preventing cancer from coming back in people who have had a solid tumor removed but still have cancer DNA in their blood. Participants receive the drug for up to 12 months. The goal is to see if the drug c…

This early-phase study tests an experimental drug called M9140 in 12 Chinese adults with advanced colorectal cancer that has not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells that carry a specific marker (CEACAM5). The mai…

This early-phase study tests a combination of two drugs (palbociclib and gedatolisib) in people with advanced lung, pancreatic, head & neck, or other solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drugs can slow can…

This early-stage study tests an experimental mRNA cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. The main goal is to check safety and immune response, with some participants also receiving the…

This early-stage trial tests a new drug called runimotamab, given alone or with another drug (trastuzumab), in people with advanced HER2-positive cancers that have spread. The main goal is to check safety and how the drug moves through the body. About 123 adults with solid tumors…

This early-stage study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This early-stage study tests a new treatment called GK01 cell injection combined with a PD-1 monoclonal antibody for people with advanced solid tumors that have spread or come back. The main goal is to check safety and how the body handles the treatment, with a small group of 15 …

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in adults with advanced solid tumors that cannot be cured. The main goal is to check safety and find the right dose. About 195 participants will take part in this early…

This study tests an experimental drug called entrectinib in children and teens with advanced solid tumors or brain tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors, especially in those with specific gene…

This trial tests a new antibody drug called acasunlimab (GEN1046) in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, to find safe doses, and second, to see how well the drug works alone or combined with other …

This study tests an experimental drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow disease progression. About 253 adults will take…

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This early-stage study tests a flavored, drinkable chemotherapy called VAL-413 (Orotecan) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the body processes…

This early-phase study tests an experimental drug called INCB186748 in 30 adults with advanced or metastatic solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. Researchers will also watch for s…

This early-phase study tests a new drug called GS-9911, given alone or with an immunotherapy drug, in 45 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. This is a first step to see if the a…

This study offers continued treatment with avelumab to cancer patients who are already benefiting from it in earlier Pfizer studies. It includes safety monitoring and survival follow-up for people with advanced cancers like lung, ovarian, and bladder cancer. The goal is to keep p…

This early-stage trial tests a new drug called BI-1910, alone or with pembrolizumab, in people with advanced solid tumors (like lung or liver cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug h…

This study gives ongoing access to the cancer drug pertuzumab for people with solid tumors who were already benefiting from it in a previous Roche study. About 154 participants will continue treatment until their disease gets worse or side effects become too severe. The goal is t…

This study follows people with solid tumors who are already taking the cancer drug avelumab to see how safe it is over a longer time. About 205 participants continue their same treatment or are monitored after finishing. Researchers track side effects, survival, and how well the …

This study tests whether giving cancer drugs based on the unique genetic changes in a person's tumor can shrink or control advanced solid tumors. About 920 adults and children with cancers that have spread or cannot be removed will receive a treatment chosen specifically for thei…

This early-phase study tests a new drug called JSI-1187, alone or with another drug (dabrafenib), in adults with advanced solid tumors that have certain gene changes (MAPK pathway mutations). The main goal is to check safety and find the right dose. About 71 people will take part…

This early-stage trial tests a new drug, MK-2870, alone or with pembrolizumab (with or without chemotherapy) in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check safety and find the right dose. About 30 participants will be enrolled.

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…

This is a first-in-human study to test the safety and find the right dose of an experimental pill called ATV-1601. It is for adults with advanced solid tumors, including certain breast, gynecologic, and prostate cancers, that have a specific genetic change called an AKT1 E17K mut…

This study looked at whether ginseng can help control fatigue and related symptoms like depression and anxiety in people with advanced cancers. 165 adults with solid tumors who had daily fatigue for at least two weeks took either ginseng or a placebo for 29 days. Researchers meas…

This study looks at the safest amount of aerobic exercise for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. It tests different exercise doses done at home using apps and devices. The goal is to see if exercise is feasible and what eff…

This study looks at whether dexamethasone, a steroid, can reduce symptoms like fatigue, pain, nausea, and poor appetite in people with advanced cancer. About 132 adults with at least three moderate-to-severe symptoms took part. Researchers measured changes in fatigue and other sy…

This study compares how well the body absorbs two different pill forms of the experimental drug AZD2281 in people with advanced solid tumors that no longer respond to standard treatments. About 197 participants will receive both forms in a random order to measure drug levels and …

This early-phase study looks at how a common drug called rifampicin changes the way the body handles the experimental cancer drug cediranib. It involves 64 adults with advanced solid tumors that no longer respond to standard treatments. The goal is to understand the drug interact…

This study collects blood samples from people who have unexpected or severe side effects from drugs they are taking for cancer. The goal is to measure drug levels in the blood to understand why side effects happen in some people but not others. Participants must be at least 2 yea…

This study follows up to 500 children and young adults who have already received gene therapy for cancer as part of an earlier trial. The goal is to monitor for any delayed side effects over the next 15 years. Participants will have regular blood tests and health check-ups, but n…

This study aims to understand why some solid tumors stop responding to targeted therapies. Researchers will collect blood, saliva, and tumor samples from 2500 people with various cancers, including colorectal, breast, and lung cancer. They will also grow some tumor samples in spe…

This study collects leftover tissue and blood samples from people with known or suspected cancer who are already scheduled for surgery or biopsy. Researchers will compare cancerous and normal tissues to find differences that could lead to new treatments. About 1,200 adults aged 1…